Biotop-report 2013

12

BioTOPics 46 | September 2013 

BioTOP-Report

Metanomics Health GmbH 

Metanomics Health – a BASF Group compa-

ny – applies comprehensive Metabolite Pro-

filing (metabolomics) with biomedical data 

interpretation. Metabolite Profiling is 

defined as the parallel analysis of multiple 

endogenous and xenobiotic metabolites in 

biological systems. The core expertise of 

Metanomics Health resides in discovery and 

validation of biomarkers.

Technologies

 

k

Metabolite profiling platform with more 

than 75 GC-MS and LC-MS/MS instru-

ments

 

k

Wide metabolite coverage via combina-

tion of unbiased and targeted platforms

 

k

Unique tox mode of action prediction 

through MetaMap

®

Tox database

 

k

Excellence in systems correlation analy-

sis of complex gene function relation-

ships

Major R&D-Topics

In cooperation with academic institutes and 

clinical experts Metanomics Health is run-

ning a large-scale diagnostic biomarker pro-

gram. Areas include metabolic syndrome, 

heart failure, prostate cancer and multiple 

sclerosis to mention a few.

Market Segments

Metanomics Health provides its services to 

pharmaceutical, diagnostics and nutrition 

companies. Technology applications include:

 

k

Mechanism of action studies

 

k

Mechanism of toxicity studies

 

k

Translational and clinical biomarker 

development (e.g. PK/PD, patient stratifi-

cation, efficacy and safety markers)

 

k

Companion diagnostic development

 

k

Cell culture & bioprocess optimization

Address

Metanomics Health GmbH 

Tegeler Weg 33

10589 Berlin · Germany

Contact

Dr. Tim Bölke · Managing Director

Phone [phone]

Fax 

[phone]

[e-mail]

www.metanomics-health.de

nanoPET Pharma GmbH

nanoPET is a biopharmaceutical company 

specialized on R&D, manufacturing and mar-

keting of innovative drug substances for 

Diagnostic Imaging. We focus on relevant 

cardiovascular, oncological and neurological 

indications as well as on regenerative medi-

cine. Nanotechnology is a key element of our 

business. We operate in three major areas.

The first nanoparticular tracers for clini-

cal PET: nanoPET prepares the clinical devel-

opment of its patented technology platform: 

inorganic nanoparticular tracers for cell- and 

molecular-specific positron emission tomog-

raphy (PET).

Viscover™ imaging agents – a landmark 

in small animal imaging: As animal imag-

ing is rapidly gaining relevance in pharma-

ceutical research, we are delighted to offer 

you an exciting portfolio of specialized pre-

clinical imaging agents covering the princi-

pal imaging modalities (MRI, CT, Ultrasound, 

Optical Imaging, SPECT & PET). Get a 

detailed insight into our product portfolio 

and download a free copy of our imaging 

guide on www.viscover.com

Consulting and Service tailored to your 

needs: As a technology and service provider, 

we offer our expertise to biopharmaceutical 

companies and imaging equipment manu-

facturers. Our customers benefit from the 

long-standing industry expertise our team 

has attained in the pharmaceutical 

research & development.

Address 

nanoPET Pharma GmbH

Robert-Koch-Platz 4

10115 Berlin · Germany

Contact

Dr. Andreas Briel · CEO

Phone  [phone]

[e-mail]

www.nanopet-pharma.com

---

13

BioTOPics 46 | September 2013 

BioTOP-Report

ORGANOBALANCE GmbH

Exploring and managing microbial 

biodiversity

ORGANOBALANCE explores the potential of 

probiotic bacteria and yeasts for new prod-

uct developments in food, feed, personal 

care, and for the pharmaceutical industry or 

the production of fine chemicals. From a 

large collection of microorganisms, specific 

strains are selected to e.g. inactivate patho-

gens, produce new bioactives, neutralize 

malodorous or toxic substances and synthe-

size high titers of valuable compounds.

ORGANOBALANCE draws on natural 

resources, which are gathered in the compa-

ny-owned collection of 8000+ microbial 

strains, mostly originating from foodstuffs. 

ORGANOBALANCE uses its OASSYS

®

 bioas-

says for highly efficient screenings. The plat-

form allows to quickly identify the most suit-

able strains from the microbial collection for 

targeted applications.

ORGANOBALANCE has a broad expertise in 

the field of yeast metabolic engineering. 

This includes designing and developing new 

production strains for industrial biotechnol-

ogy applications. Specific strains of Saccha-

romyces cerevisiae, which carry engineered 

biosynthesis pathways for the environmen-

tally friendly production of carboxylic acids, 

terpenoids, steroids and other lipid com-

pounds are available.

ORGANOBALANCE works in collaboration 

with partners and grants licenses for own 

product developments.

Address

ORGANOBALANCE GmbH

Gustav-Meyer-Allee 25

13355 Berlin · Germany

Contact

Dr. Christine Lang · CEO

Phone  [phone]

Fax 

[phone]

[e-mail]

www.organobalance.com

Our experience is your success!

The German Pharmaceutical Industry Association (BPI – 

Bundesverband der Pharmazeutischen Industrie e.V.) 

consists of approximately 240 pharmaceutical companies. 

These include not only the classic pharmaceutical firms 

and service-providers, but also biotechnology companies 

and manufacturers of medical devices.

All of our members use our association as a platform for 

information and communication to develop collaborative 

responses to the diverse challenges they face.

Our team consists of highly qualified experts in all fields 

which are necessary to generate a sustainable benefit for 

pharmaceutical companies, e.g. market access, regula-

tory affairs, law, biotechnology and political affairs.

Interested in being a member? Feel free to contact us! 

[e-mail] · www.bpi.de · Phone: +49 – 30 – 27909 – 0

Start Up-Companies are eligible for reduced member-

ship fees while having the possibility to participate in 

all activities of our association.

---